Gerard Aurigemma to Hypertension
This is a "connection" page, showing publications Gerard Aurigemma has written about Hypertension.
Connection Strength
3.947
-
Aldrugh S, Valle JE, Parker MW, Harrington CM, Aurigemma GP. Prevalence of Left Ventricular Hypertrophy Caused by Systemic Hypertension Preceding the Development of Severe Aortic Stenosis. Am J Cardiol. 2021 07 01; 150:89-94.
Score: 0.503
-
Aurigemma GP, Salerno M. A Novel Index of Remodeling in Hypertensive Heart Disease. Circ Cardiovasc Imaging. 2017 09; 10(9).
Score: 0.389
-
Gaasch WH, Aurigemma GP. CMR imaging of extracellular volume and myocardial strain in hypertensive heart disease. JACC Cardiovasc Imaging. 2015 Feb; 8(2):181-3.
Score: 0.325
-
Sevre K, Rist A, Wachtell K, Devereux RB, Aurigemma GP, Smiseth OA, Kjeldsen SE, Julius S, Pitt B, Burnier M, Kreutz R, Oparil S, Mancia G, Zannad F. What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence. Am J Hypertens. 2024 01 01; 37(1):1-14.
Score: 0.151
-
Rist A, Sevre K, Wachtell K, Devereux RB, Aurigemma GP, Smiseth OA, Kjeldsen SE, Julius S, Pitt B, Burnier M, Kreutz R, Oparil S, Mancia G, Zannad F. The current best drug treatment for hypertensive heart failure with preserved ejection fraction. Eur J Intern Med. 2024 Feb; 120:3-10.
Score: 0.149
-
Aurigemma GP, Devereux RB, Wachtell K, Palmieri V, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahl?f B. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. Am J Hypertens. 2003 Mar; 16(3):180-6.
Score: 0.142
-
Aurigemma GP, Devereux RB, De Simone G, Roman MJ, O'Grady MJ, Koren M, Alderman M, Laragh J. Myocardial function and geometry in hypertensive subjects with low levels of afterload. Am Heart J. 2002 Mar; 143(3):546-51.
Score: 0.133
-
Kovell LC, Maxner B, Ayturk D, Moore Simas TA, Harrington CM, McManus DD, Gardiner P, Aurigemma GP, Juraschek SP. Dietary Habits and Medications to Control Hypertension Among Women of Child-Bearing Age in the United States from 2001 to 2016. Am J Hypertens. 2021 09 22; 34(9):919-928.
Score: 0.129
-
Upadhya B, Pajewski NM, Rocco MV, Hundley WG, Aurigemma G, Hamilton CA, Bates JT, He J, Chen J, Chonchol M, Glasser SP, Hung AM, Pisoni R, Punzi H, Supiano MA, Toto R, Taylor A, Kitzman DW. Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART. Hypertension. 2021 05 05; 77(5):1571-1580.
Score: 0.124
-
Aurigemma GP, Williams D, Gaasch WH, Reda DJ, Materson BJ, Gottdiener JS. Ventricular and myocardial function following treatment of hypertension. Am J Cardiol. 2001 Mar 15; 87(6):732-6.
Score: 0.124
-
Aurigemma GP, Meyer TE, Sharma M, Sweeney A, Gaasch WH. Evaluation of extent of shortening versus velocity of shortening at the endocardium and midwall in hypertensive heart disease. Am J Cardiol. 1999 Mar 01; 83(5):792-4, A10.
Score: 0.108
-
Upadhya B, Rocco M, Lewis CE, Oparil S, Lovato LC, Cushman WC, Bates JT, Bello NA, Aurigemma G, Fine LJ, Johnson KC, Rodriguez CJ, Raj DS, Rastogi A, Tamariz L, Wiggers A, Kitzman DW. Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. Circ Heart Fail. 2017 Apr; 10(4).
Score: 0.094
-
Parker MW, Aurigemma GP. Cardiac Structure and Function in Hyperaldosteronism. Circ Cardiovasc Imaging. 2016 06; 9(6).
Score: 0.089
-
Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, Gottdiener J, Haluska B, Ofili E, Segers P, Senior R, Tapp RJ, Zamorano JL. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015 Jul; 28(7):727-54.
Score: 0.084
-
Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, Gottdiener J, Haluska B, Ofili E, Segers P, Senior R, Tapp RJ, Zamorano JL. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)?. Eur Heart J Cardiovasc Imaging. 2015 Jun; 16(6):577-605.
Score: 0.083
-
de Simone G, Izzo R, Aurigemma GP, De Marco M, Rozza F, Trimarco V, Stabile E, De Luca N, Trimarco B. Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities. J Hypertens. 2015 Apr; 33(4):745-54; discussion 754.
Score: 0.082
-
Bang CN, Gerdts E, Aurigemma GP, Boman K, de Simone G, Dahl?f B, K?ber L, Wachtell K, Devereux RB. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. Circ Cardiovasc Imaging. 2014 May; 7(3):422-9.
Score: 0.077
-
Bang CN, Gerdts E, Aurigemma GP, Boman K, Dahl?f B, Roman MJ, K?ber L, Wachtell K, Devereux RB. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2013 Oct; 31(10):2060-8.
Score: 0.074
-
Uraizee I, Cheng S, Hung CL, Verma A, Thomas JD, Zile MR, Aurigemma GP, Solomon SD. Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens. 2013 Oct; 26(10):1234-41.
Score: 0.073
-
Perlini S, Chung ES, Aurigemma GP, Meyer TE. Alterations in early filling dynamics predict the progression of compensated pressure overload hypertrophy to heart failure better than abnormalities in midwall systolic shortening. Clin Exp Hypertens. 2013; 35(6):401-11.
Score: 0.070
-
Lam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, Oparil S, Aurigemma GP, Thomas JD, Pitt B, Zile MR, Solomon SD. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013 Mar; 34(9):676-83.
Score: 0.069
-
Shah AM, Lam CS, Cheng S, Verma A, Desai AS, Rocha RA, Hilkert R, Izzo J, Oparil S, Pitt B, Thomas JD, Zile MR, Aurigemma GP, Solomon SD. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011 Sep; 29(9):1829-36.
Score: 0.064
-
Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, Dahl?f B, Aalto T, Ibsen H, Rokkedal JE, Devereux RB. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). Am J Cardiol. 2010 Oct 01; 106(7):999-1005.
Score: 0.060
-
Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahl?f B, Aurigemma GP, Rokkedal JE, Devereux RB. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens. 2010 Jul; 28(7):1541-6.
Score: 0.059
-
Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahl?f B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010 Jun; 19(3):169-75.
Score: 0.059
-
Chinali M, Aurigemma GP. Refining patterns of left ventricular hypertrophy using cardiac MRI: "brother, can you spare a paradigm?". Circ Cardiovasc Imaging. 2010 Mar; 3(2):129-31.
Score: 0.058
-
Chinali M, Aurigemma GP, de Simone G, Mishra RK, Gerdts E, Wachtell K, Boman K, Dahl?f B, Devereux RB. Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). Am J Cardiol. 2009 Oct 15; 104(8):1098-104.
Score: 0.056
-
Narayanan A, Aurigemma GP, Chinali M, Hill JC, Meyer TE, Tighe DA. Cardiac mechanics in mild hypertensive heart disease: a speckle-strain imaging study. Circ Cardiovasc Imaging. 2009 Sep; 2(5):382-90.
Score: 0.055
-
Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourci?re Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.
Score: 0.048
-
McManus D, Aurigemma G. Clinical advances in diastolic heart failure. Minerva Cardioangiol. 2006 Dec; 54(6):695-713.
Score: 0.046
-
Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JM, Artis E, Purkayastha D, Thomas JD, Solomon SD. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006 Aug; 152(2):246-52.
Score: 0.045
-
Vinch CS, Aurigemma GP, Simon HU, Hill JC, Tighe DA, Meyer TE. Analysis of left ventricular systolic function using midwall mechanics in patients >60 years of age with hypertensive heart disease and heart failure. Am J Cardiol. 2005 Nov 01; 96(9):1299-303.
Score: 0.042
-
Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004 Sep 09; 351(11):1097-105.
Score: 0.040
-
Wachtell K, Papademetriou V, Smith G, Gerdts E, Dahl?f B, Engblom E, Aurigemma GP, Bella JN, Ibsen H, Rokkedal J, Devereux RB. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Am Heart J. 2004 Sep; 148(3):538-44.
Score: 0.039
-
Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahl?f B, Aurigemma GP, Devereux RB. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002 Jul 09; 106(2):227-32.
Score: 0.034
-
Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, Agabiti-Rosei E, Mancia G. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation. 2001 Feb 06; 103(5):678-83.
Score: 0.031
-
Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahl?f B, Smith G, Roman MJ, Ibsen H, Aurigemma GP, Devereux RB. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol. 2001 Jan 01; 87(1):54-60.
Score: 0.031
-
Sadler DB, Aurigemma GP, Williams DW, Reda DJ, Materson BJ, Gottdiener JS. Systolic function in hypertensive men with concentric remodeling. Hypertension. 1997 Oct; 30(4):777-81.
Score: 0.024
-
Devereux RB, Pini R, Aurigemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise. J Hypertens. 1997 Aug; 15(8):801-9.
Score: 0.024
-
Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol. 1995 Jul; 26(1):195-202.
Score: 0.021
-
Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation. 1995 May 15; 91(10):2642-54.
Score: 0.021
-
Aurigemma GP, Gaasch WH. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology. 1995; 86(4):310-7.
Score: 0.020